245657-85-6

Upstream product

• 450336-25-1 [(triisopropylsilyl)oxy]acetic acid 
• 192758-34-2 benzyl (triisopropylsilyloxy)acetate 
• 201044-87-3 (3R,4S)-3-Hydroxy-1-(4-methoxy-phenyl)-4-(2-methyl-propenyl)-azetidin-2-one 
• 13154-24-0 triisopropylsilyl chloride 
• 178250-07-2 (3R,4S)-1-(4-methoxyphenyl)-3-triisopropylsiloxy-4-(2-methylprop-1-enyl)azetidin-2-one 
• 740802-74-8 (3R,4S)-1-(4-methoxyphenyl)-3-acetoxy-4-(2-methyl-1-propenyl)azetidin-2-one 

Downstream Products

• 926306-99-2 (3R,4S)-1-(4-methoxyphenyl)-3-triisopropylsiloxy-4-(2,2-difluorovinyl)azetidin-2-one 
• 286933-05-9 (3R,4S)-4-[(R)-1-(tert-Butyl-dimethyl-silanyloxy)-allyl]-1-(4-methoxy-phenyl)-3-triisopropylsilanyloxy-azetidin-2-one 
• 286932-20-5 (3R,4S)-1-(4-methoxyphenyl)-3-triisopropylsiloxy-4-(1-acetoxyprop-2-enyl)azetidin-2-one 
• 245657-86-7 (3R,4S)-1-(4-methoxyphenyl)-3-triisopropylsiloxy-4-difluoromethylazetidin-2-one 

Relevant academic research and scientific papers

Syntheses and biological activity of C-3'-difluoromethyl-taxoids

A series of new taxoids bearing difluoromethyl group at the C-3' position and modifications at the C-10 and C-14 positions has been synthesized and their biological activities studied. The in vitro cytotoxicity assay results indicate that these newly deve

Fluorinated taxane compound, preparation method therefor and application of fluorinated taxane compound

The invention discloses a fluorinated taxane compound, a preparation method therefor and an application of the fluorinated taxane compound. The compound has a structural general formula represented bya formula I. Proven by pharmacological experiments, compared with paclitaxel, a series of fluorinated taxane derivatives synthesized by the method have cytotoxicity superior to that of the paclitaxelto a multidrug-resistant human mammary cancer cell line MCF-7/Adr and an ovarian cancer cell line NCI/Adr and represent cytotoxicity superior to that of the paclitaxel to a colon cancer cell line HCT-116 with overexpressed neoplasm stem cells.

Synthesis and biological evaluation of novel 3′-difluorovinyl taxoids

A series of 3′-difluorovinyl taxoids with C10 modifications, as well as those with C2 and C10 modifications, were strategically designed to block the metabolism by cytochrome P-450 3A4 enzyme and synthesized. These novel difluorovinyl taxoids were evaluated for their cytotoxicity against drug-sensitive human breast (MCF7), multidrug-resistant (MDR) human ovarian (NCI/ADR), human colon (HT-29) and human pancreatic (PANC-1) cancer cell lines. 3′-Difluorovinyl taxoids exhibit several to 16 times better activity against MCF7, HT-29 and PANC-1 cell lines and up to three orders of magnitude higher potency against NCI/ADR cell line as compared to paclitaxel. Structure-activity relationship study shows the critical importance of the C2 modifications on the activity against MDR cancer cell line, while the C10 modifications have a rather minor effect on the potency with some exceptions. The effect of the C2 modifications on potency against MCF7 cell line increases in the following order: H 3. Among the twenty five 3′-difluorovinyl taxoids evaluated, eight taxoids exhibited less than 100 pM IC50 values against MCF7 cell line. Difluorovinyl taxoids induced GTP-independent tubulin polymerization much faster than paclitaxel. Then, the resulting microtubules were stable to Ca2+-induced depolymerization, indicating strong stabilization of microtubules. Molecular modeling study indicated that a difluorovinyl taxoid binds to β-tubulin in a manner that is consistent with the REDOR-Taxol structure. The difluorovinyl group appears to mimic the isobutenyl group to some extent, but with very different electronic property, which may account for the unique activities of difluorovinyl taxoids.

Syntheses and structure-activity relationships of novel 3′-difluoromethyl and 3′-trifluoromethyl-taxoids

A series of novel 3′-difluoromethyl-taxoids and 3′-trifluoromethyl-taxoids with modifications at the C2 and C10 positions were synthesized and evaluated for their in vitro cytotoxicities against human breast carcinoma (MCF7-S, MCF7-R, LCC6-WT, LCC6-MDR),

TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE

A compound represented by the general formula (1) [X1 and X2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, R1 represents a phenyl group, R2 represents an alkyl group, an alkenyl group, or

FLUOROTAXOIDS

The invention relates to fluorinated second generation taxoid compounds, pharmaceutical formulations thereof, and their use for inhibiting the growth of cancer cells in a mammal.

Trifluoromethyl- and difluoromethyl-β-lactams as useful building blocks for the synthesis of fluorinated amino acids, dipeptides, and fluoro-taxoids

Enantiopure 1-acyl-3-hydroxyl-4-CF2H-azetidin-2-ones and 1-acyl-3-hydroxy-4-CF3-azetidin-2-ones serve as versatile intermediates for the syntheses of CF2- and CF3-containing α-hydroxy-β-amino acids, dipeptides,

Macrocycle formation by ring-closing metathesis. Application to the syntheses of novel macrocyclic taxoids

A series of novel macrocyclic taxoids 6 and 6′ bearing 16-, 17-, and 18-membered rings connecting the substituants at the C-2 and C-3′ positions were designed and synthesized. The syntheses of these macrocycles 6 and 6′ were accomplished using the highly

New approaches to the asymmetric synthesis of dipeptide isosteres via β-Lactam Synthon Method

New and efficient synthetic routes to dipeptide isosteres with high enantiomeric purity, e.g., hydroxyethylene, dihydroxyethylene and hydroxyethylamine isosteres, have been developed via oxiranes 6 and formyloxazolines 13 derived from N-t-Boc-β-lactams 4.